Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein thiol group modification refers to a set of post-translational redox modifications of cysteine residues within proteins. The thiol (-SH) side chain of cysteine is highly reactive and susceptible to oxidation or conjugation, resulting in modifications such as disulfide bond formation, S-glutathionylation, S-nitrosylation, and others. These modifications are key for regulating protein function, signal transduction, immune responses, and adaptation to oxidative stress. Aberrant protein thiol modifications are implicated in numerous diseases due to their crucial roles in controlling enzyme activity, protein folding, and cellular redox homeostasis. Protein thiol modification is a process, not a singular molecular drug target, but is of high therapeutic interest due to its central role in health and disease.
Reversible oxidation (S-glutathionylation, S-nitrosylation, disulfide bond formation), Irreversible oxidation (sulfinic and sulfonic acid formation), Covalent adduct formation with electrophiles, Reduction via thioredoxin or glutathione systems
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein thiol group modification.